Pseudomonas aeruginosa is an opportunistic pathogen that frequently causes hospital infections. Being naturally resistant to many antibiotics and their ability to rapidly develop resistance to frequently used antibiotics make the treatment of P.aeruginosa infections difficult. In this study, we aimed to evaluate the antibiotic resistance rates of P.aeruginosa strains isolated from various clinical samples according to years and sample types and to determine the appropriate empirical treatment options for our region. The antibiotic resistance rates of 631 P.aeruginosa strains isolated from inpatients between April 2016 and December 2018 were investigated retrospectively. Automated system Phoenix™ (Becton Dickinson Diagnostics, USA) was used for identification and antibiotic susceptibility testing of bacteria. P.aeruginosa strains were mostly isolated in surgical intensive care unit (43 %). Strains were mostly isolated from respiratory tract samples (42 %). The resistance rates of the strains to amikacin, gentamicin, imipenem, meropenem, ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin have been found respectively as 7 %, 14 %, 22 %, 23 %, 26 %, 28 %, 29 % and 30%. There was no statistically significant difference in antibiotic resistance rates over the years. Antibiotic resistance of blood, abscess wound, respiratory and urine specimens were compared. A statistically significant difference was found in gentamicin resistance in blood samples, cefepime resistance in blood and abscess wound samples, piperacillin/tazobactam resistance in blood and respiratory samples compared to other sample groups (p=0.002; p=0.033; p=0.048). As a result, monitoring the antibiotic resistance rates of each hospital is necessary to guide empirical treatment. Variation of antibiotic resistance according to sample groups in P.aeruginosa infections should be considered in the selection of empirical treatment.